Palisade Bio, Inc. financial data

Symbol
PALI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
7750 El Camino Real, Suite 5200, Carlsbad, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Seneca Biopharma, Inc. (to 4/26/2021), Neuralstem, Inc. (to 1/23/2020)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 588 % +21.9%
Debt-to-equity 21.1 % -26.1%
Return On Equity -105 % +9%
Return On Assets -86.9 % +3.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.8 M shares +184%
Common Stock, Shares, Outstanding 851 K shares -81.3%
Entity Public Float 11.6 M USD +43.2%
Common Stock, Value, Issued 8 K USD -82.6%
Weighted Average Number of Shares Outstanding, Basic 768 K shares +167%
Weighted Average Number of Shares Outstanding, Diluted 768 K shares +167%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
General and Administrative Expense 6.12 M USD -17%
Operating Income (Loss) -14.2 M USD +1.03%
Nonoperating Income (Expense) 727 K USD -63%
Net Income (Loss) Attributable to Parent -13.5 M USD -8.81%
Earnings Per Share, Basic 1.74 USD/shares +43.5%
Earnings Per Share, Diluted 1.74 USD/shares +43.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.3 M USD -15.2%
Accounts Receivable, after Allowance for Credit Loss, Current 250 K USD
Assets, Current 12 M USD -16%
Property, Plant and Equipment, Net 5 K USD -44.4%
Operating Lease, Right-of-Use Asset 170 K USD -38.2%
Other Assets, Noncurrent 438 K USD -31.9%
Assets 12.7 M USD -17.1%
Accounts Payable, Current 459 K USD -35%
Employee-related Liabilities, Current 213 K USD +11.5%
Accrued Liabilities, Current 1.67 M USD +440%
Liabilities, Current 2.47 M USD +87.6%
Operating Lease, Liability, Noncurrent 58 K USD -68.1%
Liabilities 2.59 M USD +70.8%
Retained Earnings (Accumulated Deficit) -125 M USD -212%
Stockholders' Equity Attributable to Parent 10.1 M USD -26.8%
Liabilities and Equity 12.7 M USD -17.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.18 M USD +9.81%
Net Cash Provided by (Used in) Financing Activities 2.02 M USD -54.4%
Common Stock, Shares Authorized 280 M shares 0%
Common Stock, Shares, Issued 851 K shares -81.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16 M USD -226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2 K USD
Deferred Tax Assets, Valuation Allowance 29 M USD +8.54%
Deferred Tax Assets, Gross 29.1 M USD +8.17%
Operating Lease, Liability 183 K USD -37.1%
Depreciation 1 K USD 0%
Lessee, Operating Lease, Liability, to be Paid 196 K USD -40.4%
Operating Lease, Liability, Current 125 K USD +14.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93 K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 59 K USD -56.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13 K USD -65.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 93 K USD
Deferred Tax Assets, Operating Loss Carryforwards 24.7 M USD +8.92%
Additional Paid in Capital 135 M USD +7.87%
Share-based Payment Arrangement, Expense 626 K USD -18.4%
Interest Expense 16 K USD +33.3%